Research programme: human plasma-derived biologics - Abeona Therapeutics

Drug Profile

Research programme: human plasma-derived biologics - Abeona Therapeutics

Alternative Names: A1PI - Abeona Therapeutics; AAT - Abeona Therapeutics; AHF - Abeona Therapeutics; Alpha-1 protease inhibitor - Abeona Therapeutics; Antihaemophilic factor VIII - Abeona Therapeutics; Coagulation factors - Abeona Therapeutics; Human plasma-derived therapeutics - Abeona Therapeutics; IVIG - Abeona Therapeutics; Protein biologic therapeutics - Abeona Therapeutics; PTB-101 SDF Alpha™; PTB-201 SDF IVIG™; SDF Alpha™; SDF Gamma™

Latest Information Update: 15 Jan 2016

Price : $50

At a glance

  • Originator PlasmaTech Biopharmaceuticals
  • Developer Abeona Therapeutics
  • Class Acute-phase proteins; Alpha globulins; Blood coagulation factors; Blood proteins; Enzymes; Glycoproteins; Immunoglobulins; Immunoproteins; Secretory proteinase inhibitory proteins; Serum globulins
  • Mechanism of Action Alpha 1-antitrypsin replacements; Factor VIII stimulants; Immunoglobulin stimulants; Immunomodulators; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Autoimmune disorders; Chronic obstructive pulmonary disease; Immunocompromised infections
  • Research Alpha 1-antitrypsin deficiency; Blood coagulation disorders; Haemophilia A

Most Recent Events

  • 01 Jan 2015 PlasmaTech Biopharmaceuticals amends a licence agreement covering Salt Diafiltration (SDF™) Process technology obtained from Plasma Technologies
  • 31 Dec 2014 PlasmaTech Biopharmaceuticals has patent protection for Salt Diafiltration Process technology (SDF™) in USA, Europe, China and Australia (PlasmaTech Biopharmaceuticals 10-K, March 2015)
  • 31 Dec 2014 PlasmaTech Biopharmaceuticals has patents pending for Salt Diafiltration Process technology (SDF™) in Canada and India (PlasmaTech Biopharmaceuticals 10-K, March 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top